US Patent

US9403799 — Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase

Method of Use · Assigned to Merck Patent GmbH · Expires 2028-07-04 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pyrimidinyl-pyridazinone derivatives that inhibit Met kinase and can be used to treat tumors.

USPTO Abstract

Compounds selected from the group according to claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.

Drugs covered by this patent

tepotinib-hydrochloride (TEPOTINIB HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3077`	—	tepotinib-hydrochloride

Patent Metadata

Patent number: US9403799
Jurisdiction: US
Classification: Method of Use
Expires: 2028-07-04
Drug substance claim: No
Drug product claim: No
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.